Profile data is unavailable for this security.
About the company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
- Revenue in USD (TTM)2.78m
- Net income in USD-40.32m
- Incorporated2020
- Employees57.00
- LocationSAB Biotherapeutics Inc777 W 41St St, Suite 401MIAMI BEACH 33140United StatesUSA
- Phone+1 (305) 845-2813
- Fax+1 (302) 636-5454
- Websitehttps://www.sab.bio/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | 7.97m | -75.74m | 29.21m | 68.00 | -- | 0.8543 | -- | 3.67 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| RenovoRx Inc | 0.00 | -8.11m | 29.26m | 8.00 | -- | 3.15 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 29.29m | 23.00 | -- | 1.31 | -- | 23.84 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Vyne Therapeutics Inc | 486.00k | -27.86m | 29.35m | 10.00 | -- | 0.3864 | -- | 60.39 | -2.41 | -2.57 | 0.0162 | 5.15 | 0.0087 | -- | -- | 48,600.00 | -49.92 | -108.41 | -59.60 | -138.57 | -- | -- | -5,732.31 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -17.09m | 29.81m | 31.00 | -- | -- | -- | -- | -0.4891 | -0.4891 | 0.00 | -0.4202 | 0.00 | -- | -- | 0.00 | -152.35 | -- | -4,151.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 30.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 31.29m | 57.00 | -- | 0.6784 | -- | 11.25 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.66m | 31.33m | 41.00 | -- | 0.3185 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 31.65m | 20.00 | -- | 2.46 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Lumos Pharma Inc | 1.49m | -35.75m | 31.93m | 33.00 | -- | 3.11 | -- | 21.49 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 32.22m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| Clene Inc. | 442.00k | -30.46m | 32.35m | 82.00 | -- | -- | -- | 73.19 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 32.65m | 4.00 | -- | 9.38 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 917.83k | 9.95% |
| BVF Partners LPas of 31 Mar 2024 | 917.83k | 9.95% |
| Marshall Wace LLPas of 31 Mar 2024 | 459.17k | 4.98% |
| Sessa Capital IM LPas of 13 May 2024 | 458.46k | 4.97% |
| Commodore Capital LPas of 31 Mar 2024 | 183.17k | 1.99% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 175.20k | 1.90% |
| Geode Capital Management LLCas of 30 Jun 2024 | 59.42k | 0.64% |
| Millennium Management LLCas of 31 Mar 2024 | 54.05k | 0.59% |
| Pathstone Family Office LLCas of 31 Mar 2024 | 50.65k | 0.55% |
| First Manhattan Co LLCas of 31 Mar 2024 | 24.58k | 0.27% |
